HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Juan C Espín Selected Research

3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one

1/2018The gut microbiota metabolism of pomegranate or walnut ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkers: Comparison between normoweight, overweight-obesity and metabolic syndrome.
4/2016The human gut microbial ecology associated with overweight and obesity determines ellagic acid metabolism.
5/2013The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
5/2012Ellagitannin metabolites, urolithin A glucuronide and its aglycone urolithin A, ameliorate TNF-α-induced inflammation and associated molecular markers in human aortic endothelial cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Juan C Espín Research Topics

Disease

3Neoplasms (Cancer)
11/2018 - 04/2007
3Breast Neoplasms (Breast Cancer)
01/2018 - 11/2011
3Obesity
01/2018 - 10/2013
2Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2018 - 12/2013
2Overweight
01/2018 - 04/2016
2Inflammation (Inflammations)
09/2012 - 05/2012
1Thrombosis (Thrombus)
11/2019
1Chronic Disease (Chronic Diseases)
11/2016
1Weight Gain
04/2016
1Colorectal Neoplasms (Colorectal Cancer)
06/2014
1Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
08/2012
1Infections
08/2012
1Hypercholesterolemia
07/2012
1Cardiovascular Diseases (Cardiovascular Disease)
05/2012
1Body Weight (Weight, Body)
08/2011
1Colonic Neoplasms (Colon Cancer)
04/2007
1Adenoma (Adenomas)
04/2007
1Carcinoma (Carcinomatosis)
04/2007

Drug/Important Bio-Agent (IBA)

4Proteins (Proteins, Gene)FDA Link
01/2018 - 04/2007
43,8-dihydroxy-6H-dibenzo(b,d)pyran-6-oneIBA
01/2018 - 05/2012
3Pharmaceutical PreparationsIBA
11/2019 - 11/2011
3Hydrolyzable TanninsIBA
01/2018 - 05/2012
3ellagitanninIBA
12/2013 - 05/2012
2LipidsIBA
11/2018 - 12/2013
2Biomarkers (Surrogate Marker)IBA
01/2018 - 04/2016
2Ellagic AcidIBA
04/2016 - 05/2013
2PolyphenolsIBA
06/2014 - 04/2007
2Sulfates (Sulfates, Inorganic)IBA
05/2013 - 11/2011
1eculizumabFDA Link
11/2019
1AntioxidantsIBA
11/2016
1urolithin BIBA
04/2016
1isourolithin AIBA
04/2016
1DiterpenesIBA
10/2013
1salvinIBA
10/2013
1CytokinesIBA
09/2012
1Anti-Bacterial Agents (Antibiotics)IBA
08/2012
1ResveratrolIBA
07/2012
13,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one glucuronideIBA
05/2012
1GenisteinIBA
11/2011
1daidzeinIBA
11/2011
1GlucuronidesIBA
11/2011
1dihydroresveratrolIBA
08/2011
1CEACAM1 ProteinIBA
04/2007
1Messenger RNA (mRNA)IBA
04/2007

Therapy/Procedure

1Chemoprevention
04/2007